A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
Background: Coronavirus disease 19 (COVID-19) is spreading globally and treatment options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a broad-spectrum antiviral treatment candidate, optimized for inhalation and intranasal administration (UNI91104) was developed....
Main Authors: | Vibeke Backer, Ulf Sjöbring, Jesper Sonne, Anne Weiss, Morten Hostrup, Helle Krogh Johansen, Victoria Becker, David P. Sonne, Torben Balchen, Mads Jellingsø, Morten Otto Alexander Sommer |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-05-01
|
Series: | The Lancet Regional Health. Europe |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776221000612 |
Similar Items
-
Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide
by: Karl Kunzelmann
Published: (2021-05-01) -
Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis
by: Anne Weiss, et al.
Published: (2020-08-01) -
Inhaled formoterol impairs aerobic exercise capacity in endurance-trained individuals: a randomised controlled trial
by: Søren Jessen, et al.
Published: (2023-04-01) -
Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.
by: Ashlee D Brunaugh, et al.
Published: (2021-01-01) -
Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects.
by: Andreas Jurgeit, et al.
Published: (2012-01-01)